Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Things aren't getting much better for Pfizer (NYSE: PFE). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. And although Pfizer's revenue is growing again, that's not enough for the drugmaker to get back in the good graces of investors.Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline. However, it's fair to ask whether it's worth waiting for the stock to bounce back instead of investing in some of Pfizer's peers that are performing well right now. With that said, let's consider two stocks outpacing the market this year and might be worth investing in over Pfizer: Vertex Pharmaceuticals (NASDAQ: VRTX) and Viking Therapeutics (NASDAQ: VKTX).It has been an eventful past 12 months for Vertex Pharmaceuticals. The drugmaker leads the market for drugs to treat cystic fibrosis (CF) -- a rare disease that damages patients' internal organs -- registered important new approvals and clinical wins. In November 2023, Vertex announced that Casgevy, a gene editing medicine for two rare blood diseases developed with CRISPR Therapeutics, had earned its first regulatory green light in the U.K.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool